Pricing
  1. JP-listed companies
  2. RIBOMIC Inc.
  3. Financials
  4. Free cash flow

RIBOMIC Inc.【JP:4591】

Market cap
¥4.4B
P/E ratio
-3.8x
Ribomics develops next-generation aptamer drugs using its proprietary RiboART System to treat unmet medical needs like achondroplasia and eye diseases.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndFree cash flow (Million JPY)YoY (%)
Mar 31, 2025-1,030+7.78%
Mar 31, 2024-955-44.85%
Mar 31, 2023-1,733+14.76%
Mar 31, 2022-1,510+31.20%
Mar 31, 2021-1,151+21.23%
Mar 31, 2020-949+12.16%
Mar 31, 2019-846+19.34%
Mar 31, 2018-709-3.75%
Mar 31, 2017-737+97.71%
Mar 31, 2016-373-382.27%
Mar 31, 2015132

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)